Quantcast

Quanterix Announces $50,000 in Grants to Support Promising Oncology Research

Grants to be awarded to researchers with the most transformative
ideas for disrupting precision medicine through biomarker research in
Quanterix’ Accelerator Lab

LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix
Corporation (NASDAQ: QTRX)
, a company digitizing biomarker analysis
to advance the science of precision health, today announced a call for
proposals for a new Accelerator Grant Program. Designed to help
facilitate breakthroughs in science and medicine, this year’s
Accelerator Grant Program will award up to $50,000 toward the cost of
research in Quanterix’ Accelerator Lab to help advance the most exciting
biomarker research using Quanterix’ ultrasensitive Simoa technology.

“Our Simoa technology powers groundbreaking research that can disrupt
the way diseases are diagnosed and treated, and we want to make sure
that technology remains within reach for the most promising
discoveries,” said Kevin Hrusovsky, Chief Executive Officer, President
and Chairman of Quanterix. “Our rapid growth has allowed us to expand
the capabilities of our in-house pharmaceutical services lab, and the
Accelerator Grant Program extends the reach of these resources, giving
more researchers the opportunity to leverage the science of Simoa for
their projects with the goal of improving today’s healthcare system.”

This year, special consideration will be given to proposals leveraging
the Simoa
CorPlex 10 Plex planar array or other Simoa planar arrays
, which
enable the accuracy, sensitivity and reproducibility needed to address
many of today’s unmet needs in oncology, immuno-oncology and other
research areas. Specifically, proposals focused on tumor-shrinking
markers, hot and cold tumor differentiation, cytokine release syndrome,
cytokine release neurotoxicity, CAR T-cell therapies, patient
stratification, predictive biomarkers, and liquid biopsies will be given
special attention as they address some of the greatest unmet needs in
research today.

“Biomarker research continues to provide a treasure trove of information
powering medical breakthroughs and we are optimistic that together we’ll
be able to drive change,” continued Hrusovsky. “We feel there is a lot
of untapped potential in this area that could help us take down the most
lethal diseases, including cancer. That’s why we’re seeking applicants
with a focus across these specific areas in which biomarkers have
already shown significant promise.”

Quanterix’ state-of-the-art Accelerator Lab is a dedicated
CLIA-certified laboratory environment for custom assay development and
clinical sample testing. Staffed with a large team of scientists
dedicated exclusively to Accelerator projects to which grant recipients
will also have access, the Lab offers some of the greatest
ultra-sensitive assay development and instrument operation experiences
available. Since its launch in 2014, the Lab has powered considerable
advancements in disease detection and drug development, helping
researchers obtain quick, robust data that would otherwise take more
time and added resources.

To be considered for the grant, all interested parties must submit their
proposals by June 30, 2019. Recipients will be notified by July 31, 2019.

To submit your proposal and learn more about the Accelerator Grant
Program, click
here
.

About Quanterix
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix’ technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,”
“plan,” “anticipate,” “estimate,” “intend” and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix’
expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties.
Factors that may cause Quanterix’ actual results to differ from those
expressed or implied in the forward-looking statements in this press
release are discussed in Quanterix’ filings with the U.S. Securities and
Exchange Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation to
update any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes available.

Contacts

PAN Communications
Lindsay Poole, 617-502-4300
[email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.